NASDAQ: APRE
Aprea Therapeutics Inc Stock Ownership - Who owns Aprea Therapeutics?

Insider buying vs selling

Have Aprea Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Oren GiladPresidentCEO2025-04-033,003$1.87
$5.62kBuy
Oren GiladPresidentCEO2025-04-032,497$1.80
$4.49kBuy
Oren GiladPresidentCEO2024-10-23500$3.92
$1.96kBuy

1 of 1

APRE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when APRE insiders and whales buy or sell their stock.

APRE Shareholders

What type of owners hold Aprea Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Tryant LLC480.67%28,000,000$43.96MInsider
Thomas Banks229.88%13,391,146$21.02MInsider
Frank J. Hall82.09%4,781,889$7.51MInsider
David West Wilson50.21%2,924,726$4.59MInsider
Heidi A. Patterson46.15%2,688,221$4.22MInsider
Kdev Investments Ab34.21%1,992,586$3.13MInsider
Michael Reynolds33.99%1,980,040$3.11MInsider
Redmile Group LLC30.36%1,768,718$2.78MInsider
Aigh Capital Management LLC9.26%539,300$846.70kInstitution
Oren Gilad5.96%347,420$545.45kInsider

1 of 3

APRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APRE2.97%97.03%Net Buying
BGMS0.16%99.84%Net SellingNet Selling
CELZ2.71%1.36%Net Selling
ERNA0.04%99.96%Net Buying
INAB3.61%96.39%Net Buying

Aprea Therapeutics Stock Ownership FAQ

Who owns Aprea Therapeutics?

Aprea Therapeutics (NASDAQ: APRE) is owned by 31.17% institutional shareholders, 1,019.59% Aprea Therapeutics insiders, and 0.00% retail investors. Tryant LLC is the largest individual Aprea Therapeutics shareholder, owning 28.00M shares representing 480.67% of the company. Tryant LLC's Aprea Therapeutics shares are currently valued at $43.96M.

If you're new to stock investing, here's how to buy Aprea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.